Ratings Singular Genomics Systems, Inc.

Equities

OMIC

US82933R1005

Real-time Estimate Cboe BZX Other stock markets 09:30:10 2024-06-04 am EDT			5-day change	1st Jan Change
0.372 ^USD	-0.80%		0.00%	-18.50%

May. 15	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	MT
May. 14	Transcript : Singular Genomics Systems, Inc., Q1 2024 Earnings Call, May 14, 2024

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SINGULAR GENOMICS SYSTEMS, INC.	-18.50%	27.78M	D+
MODERNA, INC.	+46.30%	56.65B	B-
IQVIA HOLDINGS INC.	-7.20%	39.44B	B
LONZA GROUP AG	+39.27%	39.03B	A
CELLTRION, INC.	-11.17%	26.86B	C
ICON PUBLIC LIMITED COMPANY	+14.68%	26.75B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.01%	19.03B	B
BIO-TECHNE CORPORATION	+0.60%	12.28B	B+
UNITED THERAPEUTICS CORPORATION	+25.35%	12.26B	B+
MEDPACE HOLDINGS, INC.	+27.29%	12.04B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes